At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,201 enrolled
Drug / intervention
Blood sample collectionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Hepatitis A Virus (HAV) Antibody Persistence in Children Vaccinated With 1 Dose and Those Vaccinated With 2 Doses of Havrix in Panama
In Brief
A clinical study evaluating Blood sample collection for Hepatitis A Vaccine. Completed, enrolled 1,201 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the persistence of hepatitis A antibodies, approximately 8 years and 10 years post vaccination with the complete series of Havrix (2 doses) and the partial series completion (1 dose).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis A Vaccine
CountriesPanama
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartJun 2016
Primary CompletionAug 2018
TodayJul 2026
First PostedMar 18, 2016
Enrollment StartJun 1, 2016
Primary CompletionAug 22, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.3 years ago
Interventions
Blood sample collectionother
A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).